Breaking News Instant updates and real-time market news.

IONS

Ionis Pharmaceuticals

$40.68

-1.86 (-4.37%)

, AZN

AstraZeneca

$35.42

0.07 (0.20%)

07:12
04/09/18
04/09
07:12
04/09/18
07:12

Ionis Pharmaceuticals, AstraZeneca advance new drug for NASH

Ionis Pharmaceuticals (IONS) announced that it has licensed IONIS-AZ6-2.5-L, or AZD2693, to AstraZeneca (AZN) following advancement of the drug into development. IONIS-AZ6-2.5-L is designed to inhibit an undisclosed target to treat patients with nonalcoholic steatohepatitis. In conjunction with this milestone, global, AstraZeneca will pay a $30M license fee to Ionis. AstraZeneca will be responsible for further development and commercialization of IONIS-AZ6-2.5-L. As IONIS-AZ6-2.5-L advances in development, Ionis may also receive up to $300M in additional development and regulatory milestone payments, as well as tiered royalties up to the low teens from sales of the drug.

IONS

Ionis Pharmaceuticals

$40.68

-1.86 (-4.37%)

AZN

AstraZeneca

$35.42

0.07 (0.20%)

  • 14

    Apr

  • 23

    Apr

  • 23

    May

  • 06

    Jul

IONS Ionis Pharmaceuticals
$40.68

-1.86 (-4.37%)

02/20/18
BERN
02/20/18
NO CHANGE
Target $55
BERN
Market Perform
Ionis Pharmaceuticals price target lowered to $55 from $61 at Bernstein
Bernstein analyst Vincent Chen lowered his price target for Ionis Pharmaceuticals to $55 from $61 reflecting what is likely to be a faster decline in Spinraza sales trajectory than he had previously modeled. The analyst reiterates a Market Perform rating on the shares.
03/15/18
03/15/18
UPGRADE
Target $30

Outperform
Akcea Therapeutics upgraded to Outperform at Wells Fargo
As previously reported, Wells Fargo analyst Jim Birchenough upgraded Akcea Therapeutics (AKCA) to Outperform from Market Perform following the collaboration agreement with Ionis Pharmaceuticals (IONS) for antisense oligonucleotide therapeutic inotersen for TTR amyloidosis. The analyst also raised his price target on Akcea's shares to $30 from $20.
03/15/18
RILY
03/15/18
NO CHANGE
Target $200
RILY
Buy
Ionis not finding external partner positive for Alnylam, says B. Riley FBR
B. Riley FBR analyst Madhu Kumar says Ionis Pharmaceuticals' (IONS) inability to find an external partner for the commercial development of inotersen is a "material positive" for Alnylam Pharmaceuticals (ALNY) and its lead asset patisiran. He believes "middling efficacy, safety concerns, and IP risks" likely prevented an external partner from being interested in inotersen. The analyst keeps a Buy rating on Alnylam with a $200 price target.
03/16/18
STFL
03/16/18
NO CHANGE
Target $30
STFL
Hold
Inotersen licensing deal changes narrative for Akcea, says Stifel
Stifel analyst Stephen Willey believes Akcea Therapeutics' (AKCA) inotersen licensing deal with Ionis Pharmaceuticals (IONS) changes both the near and longer-term narrative for Akcea, as it diversifies both the revenue base and product pipeline and provides "a layer of insulation" from any potential volanesorsen-related volatility that may emerge from the Advisory Committee meeting coming on May 10. Willey raised his price target on Akcea to $30 from $20, but keeps a Hold rating on the stock, stating that he'd look to be more constructive if any near-term volanesorsen-related weakness occurs.
AZN AstraZeneca
$35.42

0.07 (0.20%)

03/14/18
HCWC
03/14/18
NO CHANGE
Target $6
HCWC
Buy
Advaxis drug unlikely culprit of patient death, says H.C. Wainwright
H.C. Wainwright analyst Swayampakula Ramakanth lowered his price target for Advaxis (ADXS) to $6 from $23 after the FDA placed a clinical hold on the Phase 1/2 study investigating the combination of the company's axalimogene filolisbac and AstraZeneca's (AZN) durvalumab for the treatment of HPV-associated cervical and head and neck cancers. Based on its previous safety profile, axalimogene is unlikely to be the cause of death for this patient, Ramakanth tells investors in a research note. The analyst, however, notes that it would likely take several months before the FDA is able to reach a decision and lift the clinical hold. He anticipates a one-to-two quarter delay to the axal plus durva combination therapy program but keeps a Buy rating on Advaxis shares.
03/19/18
JEFF
03/19/18
UPGRADE
JEFF
Buy
AstraZeneca upgraded to Buy from Hold at Jefferies
Jefferies analyst Ian Hilliker upgraded AstraZeneca to Buy and raised his price target for the shares to 5,600p from 5,075p. The company is at a "turning point," Hilliker tells investors in a research note. He believes accelerating new product launches and improving margins should deliver over 20% core earnings growth in the mid-term. Recovering growth, driven by the underlying business warrants a "modest mid-term premium valuation," the analyst contends.
03/19/18
03/19/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Unilever (UN, UL) upgraded to Neutral from Sell at Goldman Sachs with the firm's analyst saying valuation reflects growth challenges. 2. AstraZeneca (AZN) upgraded to Buy from Hold at Jefferies with analyst Ian Hilliker saying the company is at a "turning point." 3. Dr Pepper Snapple (DPS) upgraded to Outperform from Sector Perform at RBC Capital saying that some investors have struggled to justify the strategic rationale of the company's Keurig deal, but he sees "several value creation drivers" including leverage in the growing coffee category, improvements for the core Keurig brand, and the prospects for higher cash flow conversion. 4. Oshkosh (OSK) upgraded to Buy from Hold while Cummins (CMI) upgraded to Hold from Sell at Deutsche Bank. 5. HarborOne Bancorp (HONE) upgraded to Buy from Hold at Sandler O'Neill. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/06/18
PIPR
04/06/18
NO CHANGE
PIPR
Neutral
Clovis approval underscores rising competition facing Zejula, says Piper Jaffray
Prior to today's announcement that Clovis' (CLVS) label for its PARP inhibitor Rubraca has been expanded to include maintenance therapy in ovarian cancer, AstraZeneca's (AZN) Lynparza and Tesaro's (TSRO) Zejula were the only two PARP inhibitors approved in the maintenance setting, noted Piper Jaffray analyst Christopher Raymond. While Clovis' approval is not a surprise, it does underscore the intensifying competitive pressure facing Zejula, he said. Raymond, who said PARP inhibitors will primarily be differentiated on safety and added that this does not favor Zejula, keeps a Neutral rating on Tesaro.

TODAY'S FREE FLY STORIES

DHI

D.R. Horton

$44.28

0.77 (1.77%)

13:10
08/14/18
08/14
13:10
08/14/18
13:10
Options
Size block of calls sold in D R Horton looks closing »

Size block of calls sold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

M

Macy's

$41.80

1.72 (4.29%)

, PFGC

Performance Food Group

$38.05

1.15 (3.12%)

13:07
08/14/18
08/14
13:07
08/14/18
13:07
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

M

Macy's

$41.80

1.72 (4.29%)

PFGC

Performance Food Group

$38.05

1.15 (3.12%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Aug

  • 15

    Aug

  • 17

    Sep

AIV

Aimco

$43.25

0.5 (1.17%)

13:07
08/14/18
08/14
13:07
08/14/18
13:07
Conference/Events
Aimco management to meet with Jefferies »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Aug

A

Agilent

$67.14

1.19 (1.80%)

, CREE

Cree

$49.96

-0.32 (-0.64%)

13:07
08/14/18
08/14
13:07
08/14/18
13:07
Earnings
Notable companies reporting after market close »

Notable companies…

A

Agilent

$67.14

1.19 (1.80%)

CREE

Cree

$49.96

-0.32 (-0.64%)

VIAV

Viavi

$11.09

0.13 (1.19%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Aug

  • 14

    Aug

  • 14

    Aug

  • 19

    Aug

  • 20

    Aug

  • 21

    Aug

  • 05

    Sep

  • 06

    Sep

  • 12

    Sep

KO

Coca-Cola

$45.93

0.11 (0.24%)

, PEP

PepsiCo

$112.80

-0.22 (-0.19%)

13:06
08/14/18
08/14
13:06
08/14/18
13:06
Hot Stocks
Coca-Cola's BodyArmor deal seen as negative for Pepsi, Keurig Dr Pepper »

In latest attempt to…

KO

Coca-Cola

$45.93

0.11 (0.24%)

PEP

PepsiCo

$112.80

-0.22 (-0.19%)

KDP

Keurig Dr Pepper

$23.61

-0.14 (-0.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

X

U.S. Steel

$30.23

0.025 (0.08%)

, AKS

AK Steel

$4.20

-0.06 (-1.41%)

13:05
08/14/18
08/14
13:05
08/14/18
13:05
Periodicals
Canada near to imposing broad steel tariffs, Dow Jones says »

Canadian officials are…

X

U.S. Steel

$30.23

0.025 (0.08%)

AKS

AK Steel

$4.20

-0.06 (-1.41%)

NUE

Nucor

$63.53

0.4 (0.63%)

STLD

Steel Dynamics

$43.57

-0.1 (-0.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Sep

IGT

International Game

$20.44

-0.12 (-0.58%)

13:05
08/14/18
08/14
13:05
08/14/18
13:05
Options
International Game call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLI

Mack-Cali Realty

$19.99

0.92 (4.82%)

13:03
08/14/18
08/14
13:03
08/14/18
13:03
Periodicals
Land & Buildings likely to push for Mack-Cali sale, Bloomberg reports »

Jonathan Litt's Land…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSLA

Tesla

$356.33

0.29 (0.08%)

, GS

Goldman Sachs

$229.95

3.12 (1.38%)

12:56
08/14/18
08/14
12:56
08/14/18
12:56
Periodicals
Goldman not hired officially by Tesla at time of tweet, Bloomberg reports »

Goldman Sachs had not…

TSLA

Tesla

$356.33

0.29 (0.08%)

GS

Goldman Sachs

$229.95

3.12 (1.38%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

DOMO

Domo

$18.38

-0.1 (-0.54%)

12:53
08/14/18
08/14
12:53
08/14/18
12:53
Hot Stocks
Breaking Hot Stocks news story on Domo »

Joshua G. James reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WMT

Walmart

$90.91

1.25 (1.39%)

12:50
08/14/18
08/14
12:50
08/14/18
12:50
Options
8.8K Walmart Sep 92.5 - Oct 95 call spreads bought for 29c »

8.8K Walmart Sep 92.5 -…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Aug

AMZN

Amazon.com

$1,916.80

21.29 (1.12%)

12:49
08/14/18
08/14
12:49
08/14/18
12:49
Periodicals
U.K's ASA says Amazon Prime's one-day claim misled customers, CNBC reports »

The U.K.'s…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Aug

  • 13

    Sep

CCXI

ChemoCentryx

$11.12

-1.54 (-12.16%)

12:47
08/14/18
08/14
12:47
08/14/18
12:47
Recommendations
ChemoCentryx analyst commentary  »

ChemoCentryx selloff on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AEO

American Eagle

$28.00

0.66 (2.41%)

12:45
08/14/18
08/14
12:45
08/14/18
12:45
Options
American Eagle call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Aug

12:40
08/14/18
08/14
12:40
08/14/18
12:40
General news
U.S. equities are extending their rebound »

U.S. equities are…

GOOG

Alphabet

$1,240.12

5.02 (0.41%)

, GOOGL

Alphabet Class A

$1,255.80

7.04 (0.56%)

12:38
08/14/18
08/14
12:38
08/14/18
12:38
Periodicals
Alphabet invests $375M in Obamacare startup Oscar, Bloomberg reports »

Alphabet is investing…

GOOG

Alphabet

$1,240.12

5.02 (0.41%)

GOOGL

Alphabet Class A

$1,255.80

7.04 (0.56%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Aug

  • 22

    Aug

  • 18

    Sep

  • 28

    Oct

STXB

Spirit of Texas Bancshares

$21.48

(0.00%)

12:37
08/14/18
08/14
12:37
08/14/18
12:37
Hot Stocks
Breaking Hot Stocks news story on Spirit of Texas Bancshares »

FJ Capital reports 5.21%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EKSO

Ekso Bionics

$2.84

0.16 (5.97%)

12:35
08/14/18
08/14
12:35
08/14/18
12:35
Hot Stocks
Ekso Bionics awarded $5M Department of Veterans Affairs contract 

Reference Link

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:35
08/14/18
08/14
12:35
08/14/18
12:35
General news
FX Action: USD-JPY »

FX Action: USD-JPY has…

ATVI

Activision Blizzard

$71.54

1.02 (1.45%)

, EA

Electronic Arts

$131.76

0.47 (0.36%)

12:32
08/14/18
08/14
12:32
08/14/18
12:32
Hot Stocks
Game On: 'Fortnite' reportedly poses malware risk on Android »

Welcome to "Game…

ATVI

Activision Blizzard

$71.54

1.02 (1.45%)

EA

Electronic Arts

$131.76

0.47 (0.36%)

GOOG

Alphabet

$1,239.50

4.4 (0.36%)

GOOGL

Alphabet Class A

$1,255.19

6.43 (0.51%)

SSNLF

Samsung

$0.00

(0.00%)

TCEHY

Tencent

$0.00

(0.00%)

DIS

Disney

$112.93

0.82 (0.73%)

CCOEY

Capcom

$0.00

(0.00%)

NTDOY

Nintendo

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Aug

  • 14

    Aug

  • 15

    Aug

  • 22

    Aug

  • 04

    Sep

  • 10

    Sep

  • 12

    Sep

  • 12

    Sep

  • 13

    Sep

  • 18

    Sep

  • 28

    Oct

URBN

Urban Outfitters

$47.93

0.51 (1.08%)

12:30
08/14/18
08/14
12:30
08/14/18
12:30
Options
Put spreads in Urban Outfitters ahead of earnings next week »

Put spreads in Urban…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

YUMC

Yum China

$35.81

1.59 (4.65%)

12:25
08/14/18
08/14
12:25
08/14/18
12:25
Options
Yum China call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Sep

ACRS

Aclaris Therapeutics

$16.86

-0.27 (-1.58%)

12:25
08/14/18
08/14
12:25
08/14/18
12:25
Conference/Events
Cantor consumer products analysts to hold analyst/industry conference call »

Analysts, along with Dr.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Aug

CLI

Mack-Cali Realty

$19.42

0.35 (1.84%)

12:22
08/14/18
08/14
12:22
08/14/18
12:22
Periodicals
Breaking Periodicals news story on Mack-Cali Realty »

Activist investor Litt…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ANSS

Ansys

$172.90

1.87 (1.09%)

12:22
08/14/18
08/14
12:22
08/14/18
12:22
Recommendations
Ansys analyst commentary  »

Ansys price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Sep

  • 05

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.